PolyPid (PYPD) Oppenheimer 35th Annual Healthcare Life Sciences Conference 2025 summary

Key technology and product overview

• PLEX platform enables prolonged, controlled local drug delivery for days to months, surpassing competitors' 72–96 hour release windows.

• Lead product D-PLEX 100 combines PLEX with doxycycline for surgical site infection (SSI) prevention, releasing antibiotics linearly over 30 days.

• D-PLEX 100 is easy to apply during surgery, requiring minimal training and no reapplication.

• Platform and products are protected by extensive patents; company employs 65 staff in Israel.

• Oncology program using PLEX for solid tumors is in earlier development.

Clinical development and trial progress

• Completed one Phase 3 trial in 2022; second Phase 3 (SHIELD II) nearing full enrollment, with top-line results expected in Q2.

• SHIELD II is an 800-patient trial comparing D-PLEX 100 plus standard care to standard care alone, focusing on SSI reduction, reintervention, and mortality over 30 days.

• Interim analysis by DSMB in December 2024 showed efficacy signal and recommended minimum sample size, increasing probability of success.

• Previous Phase 3 (SHIELD I) showed significant reductions in infection, mortality (40%), and reintervention (55%) in high-risk patients.

• High-risk patient subgroup analysis demonstrated a 37% reduction in primary endpoint, supporting commercial positioning.

Market opportunity and commercialization

• Targeting large addressable market: 12 million US surgeries and 8 million in Europe annually.

• D-PLEX 100 holds breakthrough, fast-track, and QIDP designations, providing 8.5 years of market exclusivity post-approval.

• Commercialization strategy includes partnering with large device or pharma companies experienced in hospital sales.

• ADVANZ PHARMA is European partner, with a deal exceeding $150 million in milestones and royalties; similar partnerships sought for US and other regions.

• Inpatient use may extend beyond initial label due to hospital formulary practices.